Thrombotic disorders—such as ischemic stroke, heart attack, pulmonary embolism, and deep vein thrombosis—are principal contributors to global mortality. However, conventional thrombolytic therapies ...

A silicon-based nanothrombolytic combines clot dissolution with local microenvironment regulation, enhancing safety and efficacy in thrombotic disorders.

Researchers led by Prof. SHI Jianlin from the Shanghai Institute of Ceramics of the Chinese Academy of Sciences have developed a novel silicon-based nanothrombolytic therapy that achieves efficient ...

Testing thrombin generation in a woman with acquired hemophilia A, lupus, and heart disease showed that clotting balance ...

Traumatic injury is the third leading cause of death in the state of Texas, surpassing strokes, Alzheimer's disease and diabetes, according to the Centers for Disease Control and Prevention. A massive ...

An investigational anti-clotting medication, asundexian, demonstrated a reduction in the risk of a second ischemic (clot-caused) stroke without raising bleeding concerns, according to a preliminary ...

A global research collaboration of scientists from McMaster University (Canada), Flinders University (Australia) and ...

Time may feel smooth and continuous, but at the quantum level it behaves very differently. Physicists have now found a way to measure how long ultrafast quantum events actually last, without relying ...